Skip to main content

Paul Matisse

Analyst

Stiefel

Equibles does not estimate personal net worth.

About Paul Matisse

Paul Matisse is recorded as Analyst at Stiefel. Paul Matisse has spoken on 3 earnings calls across 2 companies, most recently for Biomarin Pharmaceutical Inc on August 6, 2026. Those appearances were for Biomarin Pharmaceutical Inc (BMRN) and Neurocrine Biosciences Inc (NBIX). The companies whose calls Paul Matisse spoke on are classified in the Healthcare sector.

Paul Matisse on recent calls

“On BD, what's next in terms of the scope of the types of things that Balmerin's looking at? And Alexander, when you take a step back now and look at the revenue base and the profitability profile you have, what's the optimal number of, I guess, like phase one, two, three assets in a pipeline of bomber and size?”
Analyst — Stiefel, BioMarin Pharmaceutical Second Quarter 2026 Conference Call ·
“As it relates to Ingressa, I was wondering at this point in the year, how much visibility do you have on pricing dynamics next year and any feedback you're getting or any insight you're getting into access dynamics with the Austado MFP being enacted?”
Analyst — Stiefel, Neurocrine Biosciences Conference Call and Webcast of Q2 2026 Financial Results ·
“Just kind of previewing your update next quarter as it relates to the amicus integration, I was wondering if you could set the stage for us on just what you might be providing as relates to the duration of the revenue outlook.”
Analyst — Stiefel, Biomarin Pharmaceutical Inc Q1 FY2026 Earnings Call ·

Affiliation history

  • Stiefel

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity